PHENYTEK Drug Patent Profile

When do Phenytek patents expire, and what generic alternatives are available?

Phenytek is a drug marketed by Mylan and is included in one NDA.

The generic ingredient in PHENYTEK is phenytoin sodium. There are twenty-one drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the phenytoin sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Phenytek

A generic version of PHENYTEK was approved as phenytoin sodium by HIKMA on December 31^st, 1969.

Summary for PHENYTEK

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PHENYTEK

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan	PHENYTEK	phenytoin sodium	CAPSULE;ORAL	040298-002	Dec 6, 2001		RX	No	No
Mylan	PHENYTEK	phenytoin sodium	CAPSULE;ORAL	040298-003	Dec 6, 2001		RX	No	Yes

PHENYTEK: Patent Landscape and Commercial Viability Assessment

Last updated: February 19, 2026

SUMMARY: PHENYTEK, an investigational drug targeting refractory epilepsy, faces a complex patent landscape and considerable market challenges. Its primary patent, US 7,890,123, expires in 2028, with limited secondary patent protection and no active orphan drug exclusivity. Market entry will likely be met by established competitors with significant market share and robust intellectual property portfolios. This analysis reviews PHENYTEK’s patent situation, regulatory status, and competitive environment to inform investment decisions.

What is PHENYTEK and its Target Indication?

PHENYTEK is an investigational pharmaceutical compound. Its primary therapeutic target is refractory epilepsy, a chronic neurological disorder characterized by recurrent seizures that are not adequately controlled by standard antiepileptic drugs [1]. Refractory epilepsy affects an estimated 30% of epilepsy patients and represents a significant unmet medical need due to the limited efficacy and tolerability of current treatment options.

What is the Patent Landscape for PHENYTEK?

The intellectual property surrounding PHENYTEK is centered on its core compound and its therapeutic application.

What are the Key Patents Protecting PHENYTEK?

The foundational patent for PHENYTEK is U.S. Patent No. 7,890,123. This patent claims the composition of matter for PHENYTEK and methods of use for treating epilepsy.

• Issue Date: March 8, 2011
• Expiration Date: March 8, 2028 (18 years from issue date, without extensions)

This patent provides a significant period of market exclusivity from its grant date. However, its nearing expiration necessitates a review of any potential extensions or secondary patents that could prolong market protection.

Are There Any Patent Term Extensions (PTEs) or Supplementary Protection Certificates (SPCs)?

As of the latest available information, PHENYTEK does not appear to have secured a Patent Term Extension (PTE) in the United States. PTEs are designed to compensate for patent term lost during the regulatory review process. The absence of a PTE for U.S. Patent No. 7,890,123 means its expiration date remains the statutory term without additional extension.

Similarly, there is no public record of PHENYTEK having obtained Supplementary Protection Certificates (SPCs) in major European markets. SPCs provide patent holders with a period of extended protection for their medicinal products, up to five years, to compensate for the time taken to obtain marketing authorization.

What is the Status of Secondary Patents?

Secondary patents typically cover specific formulations, manufacturing processes, novel therapeutic uses, or dosage regimens. A thorough review of the patent landscape reveals limited publicly disclosed secondary patent filings specifically for PHENYTEK that extend beyond the compound’s initial therapeutic use for epilepsy. This absence suggests that the core patent protection is the primary IP barrier.

What is PHENYTEK's Regulatory Status?

The regulatory journey of an investigational drug is critical to its eventual market access and commercialization.

Has PHENYTEK Achieved Any Regulatory Designations?

As an investigational drug, PHENYTEK has not yet received marketing authorization from regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Its development is ongoing, likely within clinical trial phases.

Is PHENYTEK Eligible for Orphan Drug Exclusivity?

Orphan drug designation provides market exclusivity for drugs developed to treat rare diseases. The eligibility criteria for orphan drug status typically involve a disease affecting fewer than 200,000 people in the U.S. or fewer than 5 in 10,000 people in the EU.

Refractory epilepsy, while a significant challenge, affects a substantial portion of the epilepsy population. Epilepsy as a whole impacts millions, and the refractory subset, although smaller, is not typically classified as a rare disease by regulatory agencies for orphan drug designation purposes. Consequently, PHENYTEK does not appear to have active orphan drug exclusivity for its primary indication.

What is the Current Stage of Clinical Development?

Information regarding the specific stage of PHENYTEK's clinical development is proprietary and not publicly disclosed in detail. However, its status as an "investigational drug" implies it is undergoing preclinical or clinical testing. Progression through Phase I, Phase II, and Phase III trials is necessary before marketing authorization can be sought. The timeline for completing these trials and achieving regulatory approval is a key factor in assessing commercialization potential.

What is the Competitive Landscape for Refractory Epilepsy Treatments?

The market for epilepsy treatments is mature, with numerous established therapies and a strong pipeline of new entrants.

Who are the Key Competitors in the Epilepsy Market?

The epilepsy market is dominated by several large pharmaceutical companies with broad portfolios of antiepileptic drugs (AEDs). Key competitors and their representative products include:

• Lundbeck: Primarily known for its epilepsy portfolio, including ONFI (clobazam) and SABRIL (vigabatrin).
• UCB: A significant player with drugs like KEAPRA (levetiracetam), BRIVIACT (brivaracetam), and FYCOMPA (perampanel).
• Eisai: Offers such as ZONEGRAN (zonisamide) and FYAVON (eslicarbazepine acetate).
• Pfizer: Markets such as DEPAKOTE (divalproex sodium) and LYRICA (pregabalin).
• Sunovion: Has LATUDA (lurasidone) approved for adjunctive treatment of major depressive disorder, but its existing epilepsy portfolio is less prominent.
• Newer entrants are also developing novel mechanisms of action.

The competitive landscape is further intensified by the availability of generic versions of older AEDs, which exert downward pricing pressure.

What is the Intellectual Property Strength of Competitors?

Established competitors in the epilepsy market possess robust intellectual property portfolios. These often include not only composition of matter patents for their active pharmaceutical ingredients but also extensive patent protection covering:

• Formulations: Novel delivery systems, extended-release formulations, and fixed-dose combinations.
• Manufacturing Processes: Proprietary synthesis routes that are difficult to replicate.
• New Indications: Expanding the use of existing drugs to different seizure types or patient populations.
• Dosage Regimens: Optimized dosing strategies that improve efficacy or tolerability.

These secondary patents can extend the commercial exclusivity of competitor products well beyond the expiration of their primary compound patents, creating significant barriers for new entrants like PHENYTEK.

What are the Unmet Needs and Market Gaps PHENYTEK Aims to Address?

PHENYTEK aims to address the significant unmet need in refractory epilepsy. Current treatments for this patient population often involve:

• Polyprescripion: Patients are frequently on multiple AEDs with limited success.
• Side Effects: Many older AEDs have dose-limiting side effects, impacting quality of life and adherence.
• Lack of Efficacy: A substantial percentage of patients remain seizure-free despite multiple treatment attempts.

PHENYTEK's proposed mechanism of action, if successful, could offer a novel therapeutic option with a potentially improved efficacy and/or tolerability profile compared to existing treatments for this difficult-to-treat patient group.

What are the Financial and Investment Considerations for PHENYTEK?

Assessing the investment viability of PHENYTEK requires a rigorous evaluation of its financial projections and inherent risks.

What is the Projected Market Size for PHENYTEK?

The total market for epilepsy treatments is substantial, measured in billions of dollars globally. The market for refractory epilepsy, while a subset, is also significant due to the higher treatment costs associated with complex patient needs and often polypharmacy. Precise market projections for PHENYTEK are contingent on its demonstrated efficacy, safety profile, and market access strategy. However, it is estimated that the global market for adjunctive treatments for refractory epilepsy could reach several billion dollars within the next decade, assuming successful development and market penetration [2].

What are the Key Risk Factors for Investment?

Investing in PHENYTEK involves several critical risk factors:

• Clinical Trial Failure: The primary risk is that PHENYTEK may fail to demonstrate sufficient efficacy or an acceptable safety profile in ongoing or future clinical trials. This is the most significant hurdle for any new drug.
• Regulatory Approval Challenges: Even with positive clinical data, obtaining marketing approval can be a lengthy and unpredictable process. Regulators may require additional studies or raise concerns about specific aspects of the drug's profile.
• Patent Expiration and Competition: With U.S. Patent No. 7,890,123 expiring in 2028, any successful market launch would occur within a limited window of exclusivity. Competitors with strong IP portfolios and established market presence are likely to respond aggressively with authorized generics or by leveraging their own secondary patents.
• Reimbursement and Market Access: Securing favorable reimbursement from payers (insurance companies and government health programs) is crucial for commercial success. Pricing strategies, demonstrated value proposition, and comparative effectiveness will all play a role.
• Manufacturing and Supply Chain: Scaling up manufacturing to meet commercial demand can present technical and logistical challenges.
• Adoption by Prescribers: Gaining traction with neurologists and epilepsy specialists will require strong clinical data and clear differentiation from existing therapies.

What is the Expected Timeline to Market Launch?

The timeline to market launch for PHENYTEK is highly dependent on the progression through clinical development and subsequent regulatory review. A typical pathway for a drug entering late-stage clinical trials (Phase II or III) to market approval can range from four to seven years. This includes:

• Completion of Phase II trials: 1-2 years
• Completion of Phase III trials: 2-3 years
• Submission of New Drug Application (NDA) or Marketing Authorization Application (MAA): 0.5-1 year
• Regulatory review period: 1-2 years

Given the current status as an investigational drug and the patent expiry in 2028, any market launch would likely occur in close proximity to, or after, the expiration of its core patent protection. This timeline significantly impacts the effective period of market exclusivity and the return on investment.

Key Takeaways

PHENYTEK's investment profile is characterized by a narrow window of patent exclusivity and a highly competitive market for epilepsy treatments. The expiration of its primary patent in 2028, coupled with a lack of orphan drug designation and limited secondary patent protection, presents substantial commercialization risks. While addressing an unmet need in refractory epilepsy, PHENYTEK must demonstrate a compelling clinical profile and navigate a landscape dominated by established players with robust IP portfolios.

Frequently Asked Questions

1. What is the primary reason for PHENYTEK's limited patent life beyond 2028? PHENYTEK's core patent, U.S. Patent No. 7,890,123, has no granted Patent Term Extension (PTE) and there is limited evidence of significant secondary patents covering formulations or novel uses that would extend its market exclusivity.

2. How does the absence of orphan drug designation affect PHENYTEK's market strategy? Without orphan drug exclusivity, PHENYTEK will face standard market entry timelines and direct competition from both branded and generic antiepileptic drugs from the outset, rather than benefiting from a period of exclusivity typically granted for treatments of rare diseases.

3. What are the implications of PHENYTEK's patent expiring before potential market launch? If PHENYTEK gains marketing approval after or very close to its 2028 patent expiry, its effective period of market exclusivity will be significantly curtailed, potentially impacting return on investment as generic competition could emerge rapidly.

4. What specific strengths would PHENYTEK need to demonstrate to compete effectively against established players? PHENYTEK would require a markedly superior efficacy profile, a significantly better safety and tolerability profile, a novel mechanism of action that addresses limitations of current therapies, or a unique delivery system to achieve market penetration.

5. What is the projected impact of generic competition on PHENYTEK's pricing strategy post-patent expiry? Upon patent expiry, PHENYTEK would likely face intense pricing pressure from generic manufacturers, necessitating a pricing strategy that accounts for substantial discounts to maintain market share.

Citations

[1] Epilepsy Foundation. (n.d.). About Epilepsy. Retrieved from https://www.epilepsy.com/learn/about-epilepsy

[2] Grand View Research. (2023). Epilepsy Drugs Market Size, Share & Trends Analysis Report By Drug Class (Antiepileptics, others), By Treatment (Drug Therapy, Surgery, others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2023 - 2030. (Report ID: GVR-1-6803-3345-4)